CirculatingmicroRNA changes in heart failure patients treated with cardiac resynchronization therapy: Responders vs. non-responders

European Journal of Heart Failure

Volumn 15, Issue 11, 2013, Pages 1277-1288

  Marfella, Raffaele ^a   Di Filippo, Clara ^a   Potenza, Nicoletta ^a   Sardu, Celestino ^a   Rizzo, Maria Rosaria ^a   Siniscalchi, Mario ^b   Musacchio, Emilio ^c   Barbieri, Michelangela ^a   Mauro, Ciro ^b   Mosca, Nicola ^a   Solimene, Francesco ^d   Mottola, Maria Teresa ^d   Russo, Aniello ^a   Rossi, Francesco ^a   Paolisso, Giuseppe ^a   D'Amico, Michele ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b CARDARELLI HOSPITAL   (Italy)

^c Termoli Hospital   (Italy)

^d Mercogliano Hospital   (Italy)

Author keywords

Cardiac resynchronization therapy; Heart failure; MicroRNAs

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; MICRORNA; MICRORNA 145; MICRORNA 26B; MICRORNA 29A; MICRORNA 30E; MICRORNA 92A; SPIRONOLACTONE; UNCLASSIFIED DRUG;

ADULT; APOPTOSIS; ARTICLE; BLOOD LEVEL; CARDIAC RESYNCHRONIZATION THERAPY; CARDIAC RESYNCHRONIZATION THERAPY DEVICE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE EXPRESSION; HEART FAILURE; HEART HYPERTROPHY; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE REVERSE REMODELLING; HEART MUSCLE FIBROSIS; HUMAN; INTRACARDIAC ECHOGRAPHY DEVICE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TISSUE DOPPLER IMAGING; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT RESPONSE; AGED; BLOOD; CASE CONTROL STUDY; CLINICAL TRIAL; GENETICS; HEART VENTRICLE REMODELING; MIDDLE AGED; TREATMENT OUTCOME;

CARDIAC RESYNCHRONIZATION THERAPY; HEART FAILURE; MICRORNAS;

ADULT; AGED; CARDIAC RESYNCHRONIZATION THERAPY; CASE-CONTROL STUDIES; FEMALE; HEART FAILURE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84890012984     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hft088     Document Type: Article

References (31)

1. Nohria A, Lewis E, Stevenson LW. Medical management of advanced heart failure. JAMA 2002;287:628-640
2. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, NielsenOW, Orn S, Parissis JT, Ponikowski P. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012;14:803-869
3. Fox DJ, Fitzpatrick AP, Davidson NC. Optimisation of cardiac resynchronization therapy: Addressing the problem of 'non-responders'. Heart 2005;91:1000-1002
4. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005;352:1539-1549
5. Pitzalis MV, Iacoviello M, Romito R, Massari F, Rizzon B, Luzzi G, Guida P, Andriani A, Mastropasqua F, Rizzon P. Cardiac resynchronisation therapy tailored by echocardiographic evaluation of ventricular asynchrony. J Am Coll Cardiol 2002; 40:1615-1622
6. Vanderheyden M, Mullens W, Delrue L, Goethals M, de Bruyne B, Wijns W, Geelen P, Verstreken S, Wellens F, Bartunek J. Myocardial gene expression in heart failure patients treated with cardiac resynchronization therapy responders versus nonresponders. J Am Coll Cardiol 2008;51:129-136
7. Topkara VK, Mann DL. Role of microRNAs in cardiac remodeling and heart failure. Cardiovasc Drugs Ther 2011;25:171-182
8. Dickinson BA, Semus HM, Montgomery RL, Stack C, Latimer PA, Lewton SM, Lynch JM, Hullinger TG, Seto AG, van Rooij E. Plasma microRNAs serve as biomarkers of therapeutic efficacy and disease progression in hypertension-induced heart failure. Eur J Heart Fail 2013;15:in press
9. Goren Y, Kushnir M, Zafrir B, Tabak S, Lewis BS, Amir O. Serum levels of microRNAs in patients with heart failure. Eur J Heart Fail 2012;14:147-154
10. Ramani R, Vela D, Segura A, McNamara D, Lemster B, Samarendra V, Kormos R, Toyoda Y, Bermudez C, Frazier OH, Moravec CS, Gorcsan J 3rd, Taegtmeyer H, McTiernan CF. A micro-ribonucleic acid signature associated with recovery from assist device support in 2 groups of patients with severe heart failure. J Am Coll Cardiol 2011;58:2270-2278
11. Jeevanantham V, Daubert JP, ZarebaW. Cardiac resynchronization therapy in heart failure patients: An update. Cardiol J 2009;16:197-209
12. Cheitlin MD, Armstrong WF, Aurigemma GP, Beller GA, Bierman FZ, Davis JL, Douglas PS, Faxon DP, Gillam LD, Kimball TR, Kussmaul WG, Pearlman AS, Philbrick JT, Rakowski H, Thys DM, Antman EM, Smith SC Jr, Alpert JS, Gregoratos G, Anderson JL, Hiratzka LF, Hunt SA, Fuster V, Jacobs AK, Gibbons RJ, Russell RO; American College of Cardiology; American Heart Association; American Society of Echocardiography. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). Circulation 2003;108:1146-1162
13. Waggoner AD, Agler DA, Adams DB. Cardiac resynchronization therapy and the emerging role of echocardiography (Part I): Indications and results from current studies. J Am Soc Echocardiogr 2007;20:70-75
14. Agler DA, Adams DB, Waggoner AD. Cardiac resynchronization therapy and the emerging role of echocardiography (Part II): The comprehensive examination. J Am Soc Echocardiogr 2007;20:76-90
15. Bader H, Gazzigue S, Lafitte S, Reuter S, Jais P, Haissaguerre M. Intra-left ventricular electromechanical asynchrony: A new independent predictor of severe cardiac events in heart failure patients. J Am Coll Cardiol 2004;43;248-256
16. Thum T. MicroRNA therapeutics in cardiovascular medicine. EMBO Mol Med 2012; 4:3-14
17. Divakaran V, Mann DL. The emerging role of microRNAs in cardiac remodeling and heart failure. Circ Res 2008;103:1072-1083
18. Fichtlscherer S, Zeiher AM, Dimmeler S. Circulating microRNAs: Biomarkers or mediators of cardiovascular diseases? Arterioscler Thromb Vasc Biol. 2011; 31:2383-90
19. Han M, Yang Z, Sayed D,HeM,Gao S, Lin L, YoonS, Abdellatif M.GATA4expression is primarily regulated via a miRNA-26b-dependent post-transcriptional mechanism during cardiac hypertrophy. Cardiovasc Res 2012;145:645-54
20. Li R, Yan G, Li Q, Sun H, Hu Y, Sun J, Xu B. MicroRNA-145 protects cardiomyocytes against hydrogen peroxide (H2O2)-induced apoptosis through targeting the mitochondria apoptotic pathway. PLoS One 2012;7:e44907
21. Lakner AM, Steuerwald NM, Walling TL, Ghosh S, Li T, McKillop IH, Russo MW, Bonkovsky HL, Schrum LW. Inhibitory effects of microRNA 19b in hepatic stellate cell-mediated fibrogenesis. Hepatology 2012;56:300-310
22. Bagnall RD, Tsoutsman T, Shephard RE, Ritchie W, Semsarian C. Global microRNA profiling of the mouse ventricles during development of severe hypertrophic cardiomyopathy and heart failure. PLoS One 2012;7:e44744
23. Duisters RF, Tijsen AJ, Schroen B, Leenders JJ, Lentink V, van der Made I, Herias V, van Leeuwen RE, Schellings MW, Barenbrug P, Maessen JG, Heymans S, Pinto YM, Creemers EE. miR-133 and miR-30 regulate connective tissue growth factor: Implications for a role of microRNAs in myocardial matrix remodeling. Circ Res 2009; 104:170-178
24. Soci UP, Fernandes T, HashimotoNY, Mota GF, Amadeu MA, Rosa KT, Irigoyen MC, Phillips MI, Oliveira EM. MicroRNAs 29 are involved in the improvement of ventricular compliance promoted by aerobic exercise training in rats Physiol Genomics 2011; 43:665-673
25. Wang B, Komers R, Carew R, Winbanks CE, Xu B, Herman-Edelstein M, Koh P, Thomas M, Jandeleit-Dahm K, Gregorevic P, Cooper ME, Kantharidis P. Suppression of microRNA-29 expression by TGF-b1 promotes collagen expression and renal fibrosis. J Am Soc Nephrol 2012;23:252-265
26. Sutton MG, Plappert T, Hilpisch KE, AbrahamWT, Hayes DL, Chinchoy E. Sustained reverse left ventricular structural remodeling with cardiac resynchronization at one year is a function of etiology: Quantitative Doppler echocardiographic evidence from the Multicenter InSync Randomized Clinical Evaluation (MIRACLE). Circulation 2006; 113:266-272
27. Matkovich SJ, Van Booven DJ, Youker KA, Torre-Amione G, Diwan A, Eschenbacher WH, Dorn LE,Watson MA, Margulies KB, DornGW2nd. Reciprocal regulation of myocardial microRNAs and messenger RNA in human cardiomyopathy and reversal of the microRNA signature by biomechanical support. Circulation 2009;119:1263-1271
28. Ai J, Zhang R, Gao X, Niu HF,Wang N, Xu Y, Li Y, Ma N, Sun LH, Pan ZW, Li WM, Yang BF. Overexpression of microRNA-1 impairs cardiac contractile function by damaging sarcomere assembly. Cardiovasc Res 2012;95:385-393
29. Tijsen AJ, Pinto YM, Creemers EE. Non-cardiomyocyte microRNAs in heart failure. Cardiovasc Res 2012;93:573-582
30. Ravassa S, Garci'a-Bolao I, Zudaire A, Maci'as A, Gavira JJ, Beaumont J, Arias T, Huerta A, Di'ez J. Cardiac resynchronization therapy-induced left ventricular reverse remodelling is associated with reduced plasma annexin A5. Cardiovas Res 2010;88:304-313
31. Movassagh M, Vujic A, Foo R. Genome-wide DNA methylation in human heart failure. Epigenomics 2011;3:103-109